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eta-Analysis of Randomized
rials of Percutaneous Transluminal
oronary Angioplasty Versus Atherectomy,
utting Balloon Atherotomy, or Laser Angioplasty
ohn A. Bittl, MD, FACC,* Derek P. Chew, MBBS, MPH,† Eric J. Topol, MD, FACC,‡
avid F. Kong, MD, FACC,§ Robert M. Califf, MD, FACC§
cala, Florida; Adelaide, Australia; Cleveland, Ohio; and Durham, North Carolina
OBJECTIVES We conducted a systematic overview (meta-analysis) of randomized trials of balloon
angioplasty versus coronary atherectomy, laser angioplasty, or cutting balloon atherotomy to
evaluate the effects of plaque modification during percutaneous coronary intervention.
BACKGROUND Several mechanical approaches have been developed that ablate or section atheromatous
plaque during percutaneous coronary interventions to optimize acute results, minimize
intimal injury, and reduce complications and restenosis.
METHODS Sixteen trials (9,222 patients) constitute the randomized controlled experience with atherec-
tomy, laser, or atherotomy versus balloon angioplasty with or without coronary stenting. Each
trial tested the hypothesis that ablative therapy would result in better clinical or angiographic
results than balloon dilation alone.
RESULTS Short-term death rates (31 days) were not improved by the use of ablative procedures (0.3%
vs. 0.4%, odds ratio [OR] 0.94 [95% confidence interval 0.46 to 1.92]), but periprocedural
myocardial infarctions (4.4% vs. 2.5%, OR 1.83 [95% CI 1.43 to 2.34]) and major adverse
cardiac events (5.1% vs. 3.3%, OR 1.54 [95% CI 1.25 to 1.89]) were increased. Angiographic
restenosis rates (6,958 patients) were not improved with the ablative devices (38.9% vs. 37.4%,
OR 1.06 [95% CI 0.97 to 1.17]). No reduction in revascularization rates (25.2% vs. 24.5%,
OR 1.04 [95% CI 0.94 to 1.14]) or cumulative adverse cardiac events rates up to one year after
treatment were seen with ablative devices (27.8% vs. 26.1%, OR 1.09 [95% CI 0.99 to 1.20]).
CONCLUSIONS The combined experience from randomized trials suggests that ablative devices failed to
achieve predefined clinical and angiographic outcomes. This meta-analysis does not support
the hypothesis that routine ablation or sectioning of atheromatous tissue is beneficial during
percutaneous coronary interventions. (J Am Coll Cardiol 2004;43:936–42) © 2004 by the
American College of Cardiology Foundationi
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vlthough percutaneous transluminal coronary angioplasty
as been a significant advance in the treatment of coronary
rtery disease, it has been limited by acute ischemic com-
lications and restenosis. Simpson (1) introduced the con-
ept that plaque excision would reduce the risk of abrupt
essel closure and restenosis after coronary angioplasty. The
rst clinical approach, directional coronary atherectomy
DCA), premiered in 1987, and several other mechanical
pproaches followed. By 1988, excimer laser coronary an-
ioplasty (ELA) (2), percutaneous transluminal rotational
therectomy (PTRA) (3), and transluminal extraction cor-
nary atherectomy appeared (4). The holmium laser de-
uted in 1990 (5) and cutting balloon atherotomy (CBA)
ebuted in 1991 (6).
Although each ablative device used disparate mechanisms
or incising, excising, cutting, or scoring atheromatous
laque, they shared the common goal of controlled section-
From the *Ocala Heart Institute, Munroe Regional Medical Center, Ocala,
lorida; †Flinders Medical Center, Adelaide, Australia; ‡Cleveland Clinic Founda-
ion, Cleveland, Ohio; and §Duke Clinical Research Institute, Durham, North
arolina.mManuscript received September 30, 2003; accepted October 9, 2003.ng to optimize acute results, minimize intimal injury, and
educe restenosis. Preclinical studies (7) and clinical analyses
8) suggested that the neointimal healing response was
irectly proportional to the degree of underlying injury and
hat the restenosis response was uniform for any amount of
ain achieved with a broad range of interventional devices.
everal randomized trials of coronary angioplasty versus
therectomy, laser, or cutting balloon atherotomy have further
ested these concepts, both in the presence and absence of
oronary stenting (9–20). These randomized trials all used a
ommon comparator: conventional coronary angioplasty.
Presentation of each trial evoked numerous concerns
bout sample size, enrollment criteria, and generalizability
f results. No single study could definitively test whether
issue ablation improved clinical and angiographic outcomes
fter percutaneous coronary intervention. A method to
ntegrate the available findings has been needed. This report
rovides a meta-analysis of all available randomized studies
o establish a current milestone for ablative coronary inter-
entions from a large sample of randomly allocated treat-
ents.
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andomized controlled trials of coronary ablative devices
ere identified through a PubMed search of reports pub-
ished between 1993 and 2002. To avoid publication bias (21),
e also included unpublished multicenter studies reported
rom 1993 to 2002 at Scientific Sessions of the American
eart Association, American College of Cardiology, and
ranscatheter Therapeutics. Unpublished single-center studies
ere not included in this meta-analysis. Sixteen randomized
rials met criteria for inclusion (Table 1).
nd points. Clinical outcomes included death, myocardial
nfarction (MI), and revascularization at an early time point
31 days) and at a late time point (180 to 365 days).
ngiographic restenosis was studied at 90 to 360 days.
ecause target-lesion and target-vessel revascularization
ates were not consistently reported, total revascularization
ates were analyzed.
rimary source documentation. The original definitions
f major adverse cardiac events (MACE) from each study
ere used for this analysis. Numbers of events were ob-
ained directly or calculated from rates given in tables and
ext. All events were calculated from the total population of
atients given for each time point in follow-up. When total
umbers were not provided, values were calculated on an
ntent-to-treat basis (all patients initially enrolled). All angio-
raphic restenosis events and rates were calculated from the
opulation of patients undergoing follow-up angiography,
hich was smaller than that originally enrolled.
For the Amsterdam Rotterdam Randomized Trial
AMRO) (22), individual events were obtained from Table
from reference 9 and MACE events were obtained from
doctoral thesis (22). Long-term events were from Tables
and 3 from reference 9. For Atherectomy before Multi-
ink Improves Luminal Gain and Clinical Outcomes
AMIGO) trial, events were calculated from rates provided
Antonio Colombo, MD, Columbus Hospital, Milan, Italy,
merican College of Cardiology 2002, unpublished data,
une 2003). For Angioplasty/Rotational Atherectomy for
reatment of Diffuse In-Stent Restenosis Trial (ARTIST)
10), short-term MACE events were obtained from Table 4
rom reference 10, after subtracting puncture site events
rom “any complication,” and long-term revascularization
Abbreviations and Acronyms
CBA  coronary balloon atherotomy
CI  confidence interval
DCA  directional coronary atherectomy
ELA  excimer laser coronary angioplasty
LA  (excimer or holmium) laser angioplasty
MACE  major adverse cardiac events
MI  myocardial infarction
OR  odds ratio
PTRA  percutaneous transluminal rotational
atherectomyvents and rates were obtained directly from text. Restenosis 2vents were calculated from the Table entitled Meta-
nalysis of Ablative Therapies for 245 eligible patients
hown in Figure 2 from reference 10. For Balloon/Optimal
therectomy Trial (BOAT) (11), short-term death, “larger”
Is, and any major complication events (death, Q-wave
I, or emergent bypass surgery) were calculated from rates
n Table 3 and in the section entitled “Short-Term Com-
lications” from reference 11.
For Cutting balloon atherectomy vs. Plain Old Balloon
ngioplasty Study (CAPAS) (12), events were obtained
rom Table 5 from reference 12. Although creatine
inase-MB measurements were made in all patients, only
-wave MIs were presented in the report. For Comparison
f Balloon Angioplasty/Rotational Atherectomy (COBRA)
rial (16), short-term events and rates were calculated from
he section entitled “In-Hospital Outcome” from reference
6. Cumulative events were calculated by adding events in
he section entitled “Six-Month Clinical Outcome” from
eference 16. For Coronary Angioplasty Versus Binary Exci-
ional Atherectomy Trial (CAVEAT)-I (13), short-term
vents were obtained from Table 2 from reference 13. Angio-
raphic events were obtained from the section entitled “Reste-
osis and Clinical Outcomes at Six Months” from reference 13
or the 699 patients who had successful interventions, defined
s a residual stenosis 50%. Long-term events were obtained
n Table 4 of the follow-up publication (23).
For CAVEAT-II (14), events were obtained from
ables 6, 7, and 8 of reference 14. For Canadian Coronary
therectomy Trial (CCAT) (15), short-term events were
btained from text and Table 2 of reference 15. Angio-
raphic restenosis events were calculated from total
estenosis rates described in the section “Angiographic
estenosis” from reference 15. For Dilation/Ablation Re-
ascularization Trial (DART) (17), short-term and long-
erm events and rates were obtained from Table IV of
eference 17. The binary restenosis events and rates were
alculated from Table V (of reference 17) for 219 patients
ith angiographic follow-up.
For Excimer Rotablator Balloon Angioplasty Compari-
on (ERBAC) trial (18), short-term and long-term events
ere obtained from Tables 2 and 3 of reference 18. For
lobal Randomized Trial (GRT) (19), events were ob-
ained from Tables 3 and 4 of reference 19. Revasculariza-
ion events and rates and angiographic restenosis events and
ates were obtained from Table 4 of reference 19 (Cutting
alloon Monorail Instructions for Use) (Boston Scientific
nterventional Technologies; unpublished data, 2002). For
aser Angioplasty/Coronary Angioplasty (LAVA) trial
20), events were obtained from Table 7 and data from
igure 1 of reference 20. For Restenosis Reduction by
utting Balloon Evaluation 1 (REDUCE 1) trial, events
ere calculated from slides 13, 17, and 24 (Tetsu Yamagu-
hi, MD, Toranomon Hospital, Japan, Transcatheter
herapeutics 2001, unpublished data, June 2003). For
ESCUT, events were obtained from slides 21, 23, 25, and
6 (Remo Albiero, MD, Clinica San Rocca di Franciacorta,
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ata, June 2003). For Stenting Post Rotational Atherec-
omy Trial (SPORT), events were obtained from slides 12
nd 13 for 735 patients (Theodore M. Bass, MD, Shands
acksonville Hospital, Jacksonville, Florida, unpublished
ata, February 2003).
tatistical Analysis. Data tables were constructed in du-
licate from primary sources. Odds ratios (OR) summariz-
ng the effectiveness of ablative procedures against control
reatments (coronary angioplasty) were calculated from
able 1. Alphabetical List of Randomized Trials of Atherectomy
ransluminal Coronary Angioplasty
Eponym Definition Primary End P
MIGO‡ Atherectomy before Multi-
Link Improves Luminal
Gain and Clinical
Outcomes
Binary resteno
MRO (9) Amsterdam Rotterdam
Randomised Trial
6-month MA
RTIST (10) Angioplasty/Rotational
Atherectomy for
Treatment of Diffuse In-
Stent Restenosis Trial
6-month MA
OAT (11) Balloon/Optimal
Atherectomy Trial
Binary resteno
APAS (12) Cutting Balloon Atherotomy
vs. Plain Old Balloon
Angioplasty Study
Binary resteno
AVEAT-I (13) Coronary Angioplasty Versus
Excisional Atherectomy
Trial I
Binary resteno
AVEAT-II (14) Coronary Angioplasty Versus
Excisional Atherectomy
Trial II
Binary resteno
CAT (15) Canadian Coronary
Atherectomy Trial
Binary resteno
OBRA (16) Comparison of Balloon
Angioplasty/Rotational
Atherectomy
Binary resteno
ART (17) Dilation/Ablation
Revascularization Trial
Binary resteno
RBAC (18) Excimer Rotablator Balloon
Angioplasty Comparison
Procedural suc
RBAC (18) Excimer Rotablator Balloon
Angioplasty Comparison
Procedural suc
RT (19) Global Randomized Trial Binary resteno
AVA (20) Laser Angioplasty/Coronary
Angioplasty
6-month MA
EDUCE 1‡ Restenosis Reduction by
Cutting Balloon
Evaluation 1
Binary resteno
ESCUT‡ Restenosis Cutting Balloon
Evaluation
Binary resteno
PORT‡ Stenting Post Rotational
Atherectomy Trial
30-day MACE
ooled
If the primary end point was not explicitly stated or if multiple primary end points we
atient recruitment was completed. Otherwise, the year study was reported or publis
ontrol groups of 222 PTCA patients in the ERBAC trial.
CBA  cutting balloon atherotomy; DCA  directional coronary atherectomy; E
roximal segment of the left anterior descending artery; MACE  major adverse
ransluminal coronary angioplasty; PTRA  percutaneous transluminal rotational atndividual studies using the method of Woolf (24). Pooled fRs were calculated to estimate the overall effect of ablative
herapies versus that of coronary angioplasty using an
mpirical Bayes model. The empirical Bayes model is a
andom-effects model that coincides with a fixed-effects
odel when all studies are homogeneous. In the presence of
etween-study heterogeneity, the random-effects model
ields wider confidence intervals (CIs).
The extent of heterogeneity among the 16 trials in this
eta-analysis was tested with two methods. The modified
ochran Q-statistic of DerSimonian and Laird (25) ranged
erotomy, or Laser Angioplasty Versus Percutaneous
Patients (n) Year† Indications Comparison
753 2002 Stenting in native
vessels
DCA/PTCA
308 1993 Native vessel ELA/PTCA
298 2002 In-stent PTRA/PTCA
989 1995 Native vessel DCA/PTCA
232 1997 Native vessel CBA/PTCA
1,012 1992 Native vessel DCA/PTCA
305 1993 SVG
274 1992 LAD DCA/PTCA
502 1996 Native vessel PTRA/PTCA
446 1998 Small vessel PTRA/PTCA
454† 1996 Native vessel ELA/PTCA
453† 1996 Native vessel PTRA/PTCA
1,238 1997 Native vessel CBA/PTCA
215 1997 Native vessel HLA/PTCA
802 2001 Native vessel CBA/PTCA
428 2002 In-stent CBA/PTCA
735 1999 Stenting in calcified
vessels
PTRA/PTCA
9,222§
d, the endpoint used in power calculations for sample size estimation was used. †Year
Unpublished. §All calculations of total populations and events account for duplicate
 excimer laser coronary angioplasty; HLA  holmium laser angioplasty; LAD 
event (death, myocardial infarction, or revascularization); PTCA  percutaneous
my; SVG  saphenous vein graft., Ath
oint*
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CE
CE
sis
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sis
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LCA
cardiacrom a low value of 29.66 for long-term MI to a high value
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March 17, 2004:936–42 Meta-Analysis of Ablative Therapiesf 51.52 for angiographic restenosis, yielding nonsignificant
values for heterogeneity testing (0.75  p  0.50). An
dditional check for heterogeneity involved the Peto-modified
antel-Haenszel method (26), which generated ORs that
ere indistinguishable from the fixed-effects model. Thus,
Rs from the fixed-effects model were used throughout the
eport, but ORs from the random-effects model and for each
blation type were also presented for comparison.
Significance was determined by the width of the 95%
Is. The constancy of procedural success rates reported for
he coronary angioplasty control groups for the studies
overed in this meta-analysis did not vary significantly with
ime (p  0.30).
igure 1. Mortality by treatment assignment up to 30 days. Trial abbrevia-
ions are given in Table 1. *The ERBAC control groups are identical. CBA
oronary balloon atherotomy; CI  confidence interval; DCA  directional
oronary atherectomy; LA  (excimer or holmium) laser angioplasty; OR 
dds ratio; PTRA  percutaneous transluminal rotational atherectomy;
TCA  percutaneous transluminal coronary angioplasty.
igure 2. Myocardial infarctions up to 30 days. Trial abbreviations are
iven in Table 1. *The ERBAC control groups are identical. Abbreviationsrs in Figure 1.ESULTS
ixteen trials involving 9,222 patients constituted the ran-
omized controlled experience with atherectomy, laser, or
utting balloon atherotomy versus balloon angioplasty.
Short-term death rates 31 days after treatment (Fig. 1)
ere not improved by the use of ablative procedures (0.3%
s. 0.4%, odds ratio [OR] 0.94 [95% CI 0.46 to 1.92]).
Periprocedural MI rates up to 30 days were 83% higher
Fig. 2) after atherectomy, laser, or cutting balloon proce-
ures than after PTCA (4.4% vs. 2.5%, OR 1.83 [95% CI
.43 to 2.34]). A random-effects model yielded indistin-
uishable ORs and CIs. De novo lesions also had increased
isks after ablative therapy than after coronary angioplasty
4.6% vs. 2.7%, OR 1.72 [95% CI 1.34 to 2.21]). Each type
f ablative therapy showed an increase in MIs over that seen
or coronary angioplasty: CBA (OR 1.66 [95% CI 0.91 to
.02]), DCA (OR 1.85 [95% CI 1.35 to 2.55]), LA (OR
.39 [95% CI 0.69 to 2.82]), and PTRA (OR 2.18 [95% CI
.06 to 4.50]).
The rates of MACE up to 30 days (Fig. 3) were also
igher after the use of ablative therapies than after conven-
ional coronary angioplasty (5.1% vs. 3.4%, OR 1.54 [95%
I 1.25 to 1.89]). The random-effects model generated
ndistinguishable ORs and CIs. Rates of MACE for de
ovo lesions were also increased after treatment with abla-
ive therapies (5.3% vs. 3.4%, OR 1.58 [95% CI 1.27 to
.96]).
Ten studies identified angiographic restenosis as the
rimary end point. Angiographic follow-up was achieved in
,958 of 9,222 patients (75%). The rate of angiographic
estenosis (Fig. 4) was 38.9% in the ablative group versus
7.4% in the coronary angioplasty group (OR 1.06 [95% CI
.97 to 1.17]). Group statistics showed a trend toward
igure 3. Major adverse cardiac events up to 30 days. Trial abbreviations
re given in Table 1. *The ERBAC control groups are identical. Abbre-
iations as in Figure 1.educed restenosis for DCA, neutral effects for CBA, and a
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Meta-Analysis of Ablative Therapies March 17, 2004:936–42ignificant increase in restenosis for both LA and PTRA:
CA (OR 0.90 [95% CI 0.77 to 1.05]), CBA (OR 1.01
95% CI 0.85 to 1.21]), LA (OR 1.55 [95% CI 1.09 to
.20]), and PTRA (OR 1.25 [95% CI 1.02 to 1.54]). The
ailure of ablative therapies to reduce angiographic resteno-
is may have been influenced by confounding factors.
atients assigned to ablative therapy were less likely than
hose treated with coronary angioplasty to receive bailout
tents (6.9% vs. 11.8%; OR 0.55 [95% CI 0.47 to 0.65]).
he use of bailout stents increased over time and ranged
rom 0% in the ablative trials carried out before 1995 to
.9% in the 1996 ERBAC (18) and up to a maximal use of
2% in 2001 in REDUCE 1 (Tetsu Yamaguchi, MD,
oranomon Hospital, Japan, Transcatheter Therapeutics
001, unpublished data, June 2003). However, studies
arried out before 1995 versus those carried out after the
ntroduction of bailout stenting showed no difference in
estenosis rates.
No reduction in overall revascularization rates was seen
fter the use of ablative therapies (Fig. 5). The rate of
evascularization (target-lesion, target-vessel, percutaneous
oronary intervention, or bypass surgery) was 25.2% in the
blative group versus 24.5% in the coronary angioplasty
roup (OR 1.04 [95% CI 0.94 to 1.14]).
For the 15 studies reporting long-term event rates,
umulative MI rates remained significantly higher in the
blative group than in the coronary angioplasty group up to
ne year after treatment (4.5% vs. 3.5%; OR 1.32 [95% CI
.05 to 1.65]). A random-effects model showed that the risk
f MI with ablative therapies was still significantly in-
reased.
Cumulative long-term death rates were not significantly
ncreased in the ablative group as compared with the
oronary angioplasty group (1.4% vs. 1.3%; OR 1.04 [95%
igure 4. Angiographic restenosis up to 90 to 360 days. Trial abbreviations
re given in Table 1. *The ERBAC control groups are identical. Abbre-
iations as in Figure 1.I 0.73 to 1.48]). No significant improvement in cumula- iive major adverse cardiac events (death, MI, or revascular-
zation) was seen for ablative devices over coronary angio-
lasty up to one year after treatment (Fig. 6). The overall
ate of MACE was 27.8% in the ablative group versus
6.1% in the coronary angioplasty group (OR 1.09 [95% CI
.99 to 1.20]). As compared with coronary angioplasty,
roup statistics showed favorable trends for CBA and DCA
nd unfavorable results for LA and PTRA: CBA (OR 0.94
95% CI 0.78 to 1.14]), DCA (OR 0.91 [95% CI 0.77 to
.07]), LA (OR 1.32 [95% CI 1.01 to 1.73]), and PTRA
OR 1.52 [95% CI 1.24 to 1.87]).
ISCUSSION
his meta-analysis evaluated all published and unpublished
ulticenter randomized trials reported over a 10-year period
igure 5. Cumulative revascularization rates up to 360 days. Trial abbre-
iations are given in Table 1. *The ERBAC control groups are identical.
bbreviations as in Figure 1.
igure 6. Major adverse cardiac event rates up to 360 days. Trial abbre-
iations are given in Table 1. *The control groups for the ERBAC Trial are
dentical. Abbreviations as in Figure 1.
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March 17, 2004:936–42 Meta-Analysis of Ablative Therapieso define the clinical and angiographic advantages of abla-
ive techniques. The pooled results of 16 studies, which are
eneralizable across several centers and directly compared
ith the benchmark therapy of coronary angioplasty, sug-
est that ablative techniques have not been able to achieve
rospectively defined end points in the presence or absence
f coronary stents.
The ablative procedures evaluated in this meta-analysis
emain in common use, as reflected by rates of use in
ontemporary databases, frequent publication of reports in
he current literature, and oral presentations at contempo-
ary meetings. Ablative procedures were used in 1,533 of
4,498 patients (10.6%) in the Northern New England
atabase (27) reported in 1999 and, in particular, the use of
TRA increased from 3.6% in the early era (1994 to 1995)
o 8.7% in the most recent era (1998 to 1999) reported in
002 (28). The cutting balloon is one of the most common
ypes of balloon catheter used in the U.S. (Boston Scientific
orp., Natick, Massachusetts).
It has been difficult to reconcile the favorable results of
egistry experiences with negative results of randomized
rials, but several explanations have appeared. In
AVEAT-I (13), concern was raised about inadequate
issue extraction. In BOAT (11), more aggressive debulking
as associated with reduced rates of angiographic restenosis,
ut this was not associated with reduced target-vessel
evascularization or improved clinical outcome. A different
pproach using PTRA for in-stent restenosis was taken in
RTIST (10). Although a promising restenosis rate of
30% was seen in a pilot study when PTRA was followed
y low-pressure balloon inflation (29), serial intravascular
ltrasound measurements in ARTIST suggested that
TRA ablated only minimal neointimal tissue from within
tents and that post-PTRA low-pressure balloon inflation
chieved less stent expansion that high-pressure balloon
nflation alone without PTRA (30). When a more aggres-
ive PTRA strategy was compared with conventional PTRA
n Study to Determine Rotablator and Transluminal An-
ioplasty Strategy (STRATAS), restenosis rates were para-
oxically increased (58% vs. 52%) (31).
Although multicenter randomized trials remain the best
echanism to control for confounding factors during the
valuation of new therapies, they may not be the optimal
enue for studying relatively complex ablative techniques
hat are dependent on operator expertise and selection of
ppropriate lesions for ablation, such as bifurcation lesions,
stial stenoses, certain calcified stenoses, or undilatable
esions (32,33). The techniques used in various centers in
andomized trials may not have uniformly achieved desired
egrees of debulking. In the AMIGO trial, for example,
rotocol-prescribed aggressive debulking was achieved in
nly 26.5% of lesions in the overall study population. At two
enters in the AMIGO Trial where more optimal atherec-
omy was performed, binary restenosis rates were signifi-
antly reduced from 32% to 14% (Antonio Colombo, MD,
olumbus Hospital, Milan, Italy, American College of dardiology 2002, unpublished data, June 2003). Other
echnical factors may also lead to the selection of ablative
evices. For example, cutting balloons are much less likely
o slip inside narrowed stents than are bare balloons,
efining an immediate practical advantage.
This meta-analysis raises the larger biologic issue of
hether the broad application of ablation techniques is the
ptimal means of treating coronary atherosclerosis, because
hese techniques may be more injurious than initially
hought. For example, laser angioplasty was originally pro-
osed to ablate atheromatous plaque by the vascular-sparing
rocess of photochemical dissociation, but this was dis-
roved when excimer and holmium laser angioplasty were
oth shown to cause similar and striking barotraumatic
njury with virtually no plaque removal in experimental
tudies (34). Likewise, rotational atherectomy was observed
o injure vascular tissue from excessive heat generation (35)
nd platelet aggregation (36). Aggressive DCA performed
n BOAT (11) produced a larger relative increase in the rate
f periprocedural MIs than that seen in CAVEAT-I (13).
irectional atherectomy doubled the rates of embolization
n saphenous vein grafts as compared with coronary angio-
lasty in CAVEAT-II (13.4% vs. 5.1%) (14). Cutting
alloon atherotomy caused higher rates of vessel perforation
han coronary angioplasty in GRT (0.8% vs. 0.0%), as did
TRA in ARTIST (1.3% vs. 0.0%) (10).
This meta-analysis was limited by the protocols used to
easure postprocedural events. Because most trials did not
ystematically measure postprocedural creatine kinase MB
alues, the rates of MI have been underreported and the
ifferences in periprocedural MI rates have been underesti-
ated. Unequal use of bailout stenting in more recent
tudies may have biased the angiographic restenosis rates in
avor of coronary angioplasty, but earlier studies before the
ntroduction of bailout stenting showed no advantage of
blative therapy over coronary angioplasty. The inclusion of
BA in this meta-analysis has been justified on the grounds
hat CBA, like the ablative devices, was developed to
educe intimal injury during coronary angioplasty (6,12,37),
nd almost every report has discussed CBA as an alter-
ative to coronary angioplasty, DCA, PTRA, or laser
ngioplasty.
In conclusion, mechanical approaches involving plaque
blation or sectioning have not been associated with im-
roved clinical outcomes or lower restenosis in randomized
rials. This meta-analysis does not condemn a technology
hat has 20 years of scientific development and promise for
pecific indications. Instead, it simply provides a milepost
or where we currently stand. New innovations in tissue
blation should be identified before any new large clinical
rials are launched. The solution to the problem of resteno-
is in native coronary arteries will likely come not from
echanical removal of atheromatous plaque, but from
ascular brachytherapy or molecular interventions such as
rug-eluting stents that alter vascular biology (38,39).
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